Category Archives: Anti-Aging Medicine

Dr. Yousef Abo Zarad A Dermatologist Winning Hearts And Crushing The Internet With His Popularity  Outlook India

Read more:
Dr. Yousef Abo Zarad A Dermatologist Winning Hearts And Crushing The Internet With His Popularity - Outlook India

Background: In multiple chronic clinical studies, topical niacinamide (vitamin B3) has been observed to be well tolerated by skin and to provide a broad array of improvements in the appearance of aging facial skin (eg, reduction in the appearance of hyperpigmentated spots and red blotchiness).

Objective: To clinically determine the effect of topical niacinamide on additional skin appearance and property end points (wrinkles, yellowing, and elasticity).

Methods: Female white subjects (N = 50) with clinical signs of facial photoaging (fine lines and wrinkles, poor texture, and hyperpigmented spots) applied 5% niacinamide to half of the face and its vehicle control to the other half twice daily for 12 weeks (double blind, left-right randomized). Facial images and instrumental measures were obtained at baseline and at 4-week intervals.

Results: Analyses of the data revealed a variety of significant skin appearance improvement effects for topical niacinamide: reductions in fine lines and wrinkles, hyperpigmented spots, red blotchiness, and skin sallowness (yellowing). In addition, elasticity (as measured via cutometry) was improved. Corresponding mechanistic information is presented.

Conclusion: In addition to previously observed benefits for topical niacinamide, additional effects were identified (improved appearance of skin wrinkles and yellowing and improved elasticity).

Read the original:
Niacinamide: A B vitamin that improves aging facial skin ... - PubMed

Aging in humans is a well-established primary risk factor for many disabling diseases and conditions, among them diabetes, cardiovascular disease, Alzheimer's disease and cancer. In fact, the risk of death from these causes is dramatically accelerated (100-1000 fold) between the ages of 35 and 85 years. For this reason, there is a need for the development of new interventions to improve and maintain health into old age - to improve "healthspan".

Several mechanisms have been shown to delay the aging process, resulting in improved healthspan in animal models, including mammals. These include caloric restriction, alteration in GH/IGF1 pathways, as well as use of several drugs such as resveratrol (SIRT1 activator) and rapamycin (mTOR inhibitor). At Einstein, the investigators have been working to discover pathways associated with exceptional longevity. The investigators propose the study of drugs already in common clinical use (and FDA approved) for a possible alternative purpose -healthy aging. The investigators goal is to identify additional mechanisms involved in aging, the delay of aging and the prevention of age-related diseases. In this proposal, the investigators explore the possibility of a commonly used drug, metformin, to reverse relevant aspects of the physiology and biology of aging.

Metformin is an FDA approved drug in common use in the US since the 1990s. It is the first-line drug of choice for prevention and treatment of type 2 diabetes (T2DM). The effect of metformin on aging has been extensively studied, and has been associated with longevity in many rodent models. Metformin also extends the lifespan of nematodes, suggesting an evolutionarily conserved mechanism. A recent high impact study demonstrated that metformin reduces oxidative stress and inflammation and extends both lifespan and health span in a mouse model .

If indeed metformin is an "anti-aging" drug, its administration should be associated with less age-related disease in general, rather than the decreased incidence of a single age-related disease. This notion led investigators to further study whether anti-aging effects can be demonstrated in the type 2 diabetes population. Notably, in the United Kingdom Prospective Diabetes Study (UKPDS) metformin, compared with other anti-diabetes drugs, demonstrated a decreased risk of cardiovascular disease. This has been suggested in other studies and meta-analyses and remains an active area of research.

In addition, numerous epidemiologic studies have shown an association of metformin use with a decreased risk of cancer, as well as decreased cancer mortality. There is also evidence from studies performed both in-vitro and in-vivo of metformin's role in attenuating tumorigenesis. The mechanisms proposed relate to its effects on reducing insulin levels, improved insulin action, decreased IGF-1 signaling (central to mammalian longevity), as well as activation of AMP-kinase. In fact, metformin's potential protective effect against cancer has been gaining much attention, with over 100 ongoing studies registered on the Clinical Trials.gov website.

To characterize pathways associated with increased lifespan and healthspan, the investigators plan to compile a repository of muscle and adipose biopsy samples obtained from young healthy subjects and older adults before and after treatment with potential anti-aging drugs. RNA-Seq analysis will be used to identify a unique biological "fingerprint" for aging in these tissues by comparing changes in gene expression in older adults post-drug therapy to the profiles of young healthy subjects. This overall approach is supported by a grant from the Glenn Foundation for the Study of the Biology of Human Aging.

The investigators believe that if metformin changes the biology of aging in tissues to a younger profile, it supports the notion that this drug may have more widespread use - as an "anti-aging" drug.

Read more:
Metformin in Longevity Study (MILES). (MILES) - ClinicalTrials.gov

Other hires made by Altos include Peter Walter, whose laboratory at the University of California, San Francisco, is behind a molecule that shows remarkable effects on memory. Also joining is Wolf Reik, a reprogramming specialist who recently resigned as the director of the Babraham Institute in the UK after the center said he was taking a job with another research organization now believed to be Altos. Walter and Reik declined to comment.

At least initially, Altos will be funding researchers with no immediate expectation for products or revenues. According to one person briefed by Klausner and Milner, the initial output of the company will be great science.

Altos is luring university professors by offering sports-star salaries of $1 million a year or more, plus equity, as well as freedom from the hassle of applying for grants. One researcher who confirmed accepting a job offer from Altos, Manuel Serrano of the Institute for Research in Biomedicine, in Barcelona, Spain, said the company would pay him five to 10 times what he earns now.

The philosophy of Altos Labs is to do curiosity-driven research. This is what I know how to do and love to do, says Serrano, who plans to move to Cambridge, UK to join an Altos facility there. In this case, through a private company, we have the freedom to be bold and explore. In this way it will rejuvenate me.

Any treatment for a major disease of aging could be worth billions, but Altos isnt counting on making money at first. The aim is to understand rejuvenation, says Serrano. I would say the idea of having revenue in the future is there, but its not the immediate goal.

In 2013, Serrano was among the first scientists to genetically engineer mice to produce Yamanaka factors. They all developed tumors as their cells reverted to an embryonic stage. Still, the work hinted that time could be reversed inside a living animal. You introduce the factors and they do the magic. Its very simple experimentally, even if it is not understood, says Serrano.

Continued here:
Meet Altos Labs, Silicon Valleys latest wild bet on living forever

Dr. Natthapat Benz Minchaiynunt of Alpha Medical Clinic on Staying Ahead of the Curve in Thailands Aesthetics Industry  Prestige Online Thailand

Originally posted here:
Dr. Natthapat Benz Minchaiynunt of Alpha Medical Clinic on Staying Ahead of the Curve in Thailands Aesthetics Industry - Prestige Online Thailand

AAMSSA is a non-profit society committed to the scientific and legitimate practice of Aesthetic and Anti-Aging Medicine to the benefit of the profession and the patient. AAMSSA is affiliated to the International Union of Aesthetic Medicine (UIME), South African Medical Association (SAMA), actively collaborates with the HPCSA when Scope of Practise for Aesthetic practitioners are considered as well as with the medical societies: The Association of Plastic, Reconstructive and Aesthetic Surgeons of Southern Africa (APRASSA), Dermatology Society Of South Africa (DSSA) and The South African Society for Dermatologic Surgery (SASDS).

We represent all medical doctors with a special interest in Aesthetic and Anti-Aging Medicine of South Africa and neighbouring countries. AAMSSA Membership supports career development, skills development, and the opportunity to belong to a community of like-minded individuals where the standards of treatment are world-class, ethical, and medically appropriate.

The mission of AAMSSA is to provide leadership and support to advance quality clinical, educational and professional standards of care for patients undergoing aesthetic procedures and treatment in the field of Aesthetic Medicine.

View original post here:
Home - AAMSSA